- Home
- NBY
NBY
NovaBay Pharmaceuticals Inc.
as 11-15-2024 3:37pm EST
Stocks
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | N/A | IPO Year: | 2007 |
| Target Price: | $0.85 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.07 - $6.30 | Next Earning Date: | 11-07-2024 |
| Revenue: | $13,060,000 | Revenue Growth: | 2.18% |
| Revenue Growth (this year): | -25.99% | Revenue Growth (next year): | 26.04% |
Latest NovaBay Pharmaceuticals Inc. News
NBY Breaking Stock News: Dive into NBY Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals’ Proposals to Authorize the Sale of its Avenova Brand
Business Wire
10 days ago
NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results
Business Wire
11 days ago
NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price
Business Wire
19 days ago
NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC
PR Newswire
2 months ago
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals
Business Wire
2 months ago
NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets
Business Wire
3 months ago
NovaBay Pharmaceuticals Reports Second Quarter 2024 Financial Results
Business Wire
4 months ago
NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024
Compare NBY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NBY NovaBay Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.